 NEW YORK, Dec. 11, 2020 GLOBE NEWSWIRE -- Prevail Therapeutics Inc. Nasdaq: PRVL, a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 12 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations FTD-GRN. 